Skip Nav Destination
.jpg?versionId=5430)
President's Column
Hello World! ASH Is Global and Making a Difference
April 28, 2023
ASH President Dr. Robert Brodsky writes about a recent trip abroad and how it deepened his pride in being a member of ASH.
Hematologic Malignancies and the Food and Drug Administration’s Accelerated Approval Program
How is the U.S. Food and Drug Administration's Accelerated Approval program doing when it comes to introducing promising agents to patients with hematologic malignancies?
Why Are There So Few Drugs to Treat Sickle Cell Disease?
Dr. David Rees looks at what’s on the horizon in terms of treatment options for individuals with SCD.
In Which Trial Do I Belong? The PedAL APAL2020SC and EuPAL 2021 Registry Sorting Hats for Relapsed/Refractory Pediatric Acute Leukemias
Drs. Andrew Hughes and Sarah Tasian share their summary and thoughts about a clinical trial with implications for the treatment of pediatric acute leukemias
